ReviewBritish journal of clinical pharmacology2003
Evaluation of new therapies for inflammatory bowel disease.
Review in British journal of clinical pharmacology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 36 citations in OpenAlex.
- Pimenta racemosa extract ameliorates chemically induced ulcerative colitis in rats by suppressing inflammation and oxidative stress.Inflammopharmacology · 2026Article
- Review
- Protective effect of 6-paradol in acetic acid-induced ulcerative colitis in rats.BMC complementary medicine and therapies · 2021Article
- Short-Chain Naphthoquinone Protects Against Both Acute and Spontaneous Chronic Murine Colitis by Alleviating Inflammatory Responses.Frontiers in pharmacology · 2021Article
- Botanical Drugs as an Emerging Strategy in Inflammatory Bowel Disease: A Review.Mediators of inflammation · 2015Review
- Managing ulcerative colitis by increasing hydrogen production via oral administration of Acarbose.African journal of traditional, complementary, and alternative medicines : AJTCAM · 2013Article
- Acarbose: a new option in the treatment of ulcerative colitis by increasing hydrogen production.African journal of traditional, complementary, and alternative medicines : AJTCAM · 2012Article
- A strategy to identify stable membrane-permeant peptide inhibitors of myosin light chain kinase.Pharmaceutical research · 2005Article
- Standard and Extended Thromboprophylaxis in Patients with Inflammatory Bowel Disease: A Literature Review.Euroasian journal of hepato-gastroenterologyReview
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathophysiology of inflammatory bowel disease (IBD) is gradually being unravelled and new therapies are being developed to target the disturbed biological processes. This article outlines the clinical features of IBD, its current therapy and pathogenesis. The difficulties for clinical pharmacologists and gastroenterologists associated with designing, executing and interpreting clinical trials in IBD are then discussed. The final section reviews methods that can used to demonstrate the pharmacological actions of new treatments in patients with IBD. It is emphasized that proof of the therapeutic efficacy of a novel agent with a specific mechanism of action yields not only clinical benefit to patients with IBD, but also indicates the importance of the targeted biochemical pathway in the pathogenesis of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.